ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1292

HLA-B*58:01 Genotype and the Risk of Allopurinol-Associated Severe Cutaneous Adverse Reactions in a Predominately Black or African American Population with Advanced Chronic Kidney Disease

Sarah Ford1, Pamela Kimball1, Gaurav Gupta1 and Nehal Shah2, 1Virginia Commonwealth University, Richmond, VA, 2Medicine/Rheumatology, Virginia Commonwealth University, Richmond, VA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: African-Americans, Allopurinol, drug therapy and gout, Genetic Biomarkers

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Title: Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Allopurinol is the first line urate lowering drug used for treatment of gout. Its most feared side effect includes development of hypersensitivity drug reactions which may range from mild maculopapular eruption to life threatening severe cutaneous adverse reactions (SCARs) including drug rash with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). HLA-B*58:01 is strongly associated with the development of allopurinol-associated SCAR’s in the Han Chinese, Thai and Korean populations. Interestingly, the association between HLA-B*58:01 and SCARs is not as strong in Japanese, European and Australian populations. This suggests that this HLA association with allopurinol-induced SCARs varies with ethnicity. Studies in the United States have suggested that Asians and Blacks have substantially increased risk of allopurinol-associated SJS/TEN as compared to Whites and Hispanics which correlates with the allele frequency (7.4%, 4%, 1% and 1%, respectively).

This study was conducted to evaluate the frequency of the HLA-B*58:01 allele and its possible relationship of allopurinol-associated SCAR’s in a predominately Black or African American population with advanced chronic kidney disease (CKD) undergoing evaluation for renal transplantation. Given that CKD is a risk factor for development of gout, this population of patients is at high risk for development of gout and thus for exposure to allopurinol.

Methods:

All patients with advanced CKD undergoing evaluation for renal transplantation from 5/1/2012 to 8/2/2017 who were genotyped as part of the transplant evaluation within the inclusion period were included in the study and assessment was made of the presence or absence of the HLA-B58:01 allele. The entire cohort was assessed for the presence of a documented allergy to allopurinol.

Results:

From 5/1/2012 to 8/2/2017, 2080 patients were assessed for renal transplantation and genotyped. Of these, 1355 (65%) were Black or African American, 587 (28%) were White, 42 (2%) were Asian. 92 patients were HLA-B*58:01 positive, 77 were HLA-B*58:02 positive and 42 were HLA-B58 positive, but the specific allele was not clear. Of the patients who were HLA-B*58:01 positive, 82 (89%) were Black or African American, 6 (6.5%) were White, 2 (2.2%) were Asian and 2 (2.2%) were another race. The prevalence of HLA-B*58:01 was 6% in this African American or Black population. Only one patient had allopurinol listed as a drug allergy with the reported reaction of DRESS. This patient was HLA-B*58:01 positive and was African American.

Conclusion:

In this cohort of predominately African American patients undergoing evaluation for renal transplant, there was a higher frequency of the HLA-B*58:01 allele in the African American or Black population, however overall incidence of allopurinol-associated SCARs was uncommon. This suggests that despite the increased frequency of the HLA-B*58:01 allele in this population and its noted association with allopurinol-associated SCARs in other ethnicities, genetic testing for the HLA-B*58:01 allele prior to initiation of allopurinol therapy for gout is not warranted in the African American or Black population.


Disclosure: S. Ford, None; P. Kimball, None; G. Gupta, None; N. Shah, None.

To cite this abstract in AMA style:

Ford S, Kimball P, Gupta G, Shah N. HLA-B*58:01 Genotype and the Risk of Allopurinol-Associated Severe Cutaneous Adverse Reactions in a Predominately Black or African American Population with Advanced Chronic Kidney Disease [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/hla-b5801-genotype-and-the-risk-of-allopurinol-associated-severe-cutaneous-adverse-reactions-in-a-predominately-black-or-african-american-population-with-advanced-chronic-kidney-disease/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hla-b5801-genotype-and-the-risk-of-allopurinol-associated-severe-cutaneous-adverse-reactions-in-a-predominately-black-or-african-american-population-with-advanced-chronic-kidney-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology